The Paul I. Terasaki Clinical Science Award was established in 2003 to honor an individual, group, or institution in recognition of significant accomplishments an/or contributions to the fields of clinical transplantation, histocompatibility, and immunogenetics. This award was made possible by a grant from the Paul I. Terasaki Foundation. In recognition of the scientific contributions to the field of immunogenetics and transplantation immunology made by Dr. Bernard Amos, the "Distinguished Scientist Award" has been renamed the "Bernard Amos Distinguished Scientist Award" This award was established in 2001 to honor a distinguished ASHI scientist, who like Dr. Amos, has made significant contributions to our field.
This plenary session will discuss the advances in Hematopoietic Stem Cell transplantation (HSCT). In this session we will hear how HCST started, what the needs were, the groups of patient in which they were used and how the requirements and applications changed overtime. This presentation will allow us to understand the interplay between HSCT and cellular therapy today. In addition we will learn how the use of HLA mismatched donors can expand the the application of HSCT to more patients with the implementation of novel immunosuppressive therapies. In the final presentation we will learn about state of the art of studies regardingHLA loss as a main mechanism of tumor escape after HCST.
This workshop will delve into multiple aspects of standardizing the workflows of all laboratory managed data, including acquiring, managing, storing, reporting, messaging, and discarding data. The speakers and panelists will touch on some recommended HLA and antibody data standards, examples of best practices as well as practices to avoid when handling laboratory/clinical data.
This session will highlight three precision medicine approaches aimed at understanding, preventing, and treating alloimmune injury which remains a dominant cause of long-term kidney allograft loss. Presenter 1 will demonstrate novel approaches to understand the functional properties of donor specific antibodies and their interaction with the kidney allograft tissue. Presenter 2 will show the clinical utility of using molecular mismatch analysis to risk stratify and guide the selection of induction therapy. Presenter 3 will discuss the approach and activities undertaken to incorporate molecular matching in local and national kidney allocation systems in Canada.